Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410
Debt
Debt-to-Equity RatioN/A
Current Ratio9.56
Quick Ratio9.56
Price-To-Earnings
Trailing P/E Ratio-18.51
Forward P/E Ratio-17.57
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.31 per share
Price / Book9.46
Profitability
EPS (Most Recent Fiscal Year)($2.78)
Net Income$-70,420,000.00
Net MarginsN/A
Return on Equity-62.28%
Return on Assets-55.07%
Miscellaneous
Employees51
Outstanding Shares29,050,000
Market Cap$1,422.10
Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How were Mirati Therapeutics' earnings last quarter?
Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Zacks' consensus estimate of ($0.63) by $0.12. The biotechnology company earned $9.47 million during the quarter, compared to analyst estimates of $10 million. View Mirati Therapeutics' Earnings History.
What price target have analysts set for MRTX?
10 analysts have issued 1 year price targets for Mirati Therapeutics' shares. Their predictions range from $5.00 to $64.00. On average, they anticipate Mirati Therapeutics' share price to reach $40.4444 in the next twelve months. This suggests that the stock has a possible downside of 19.5%. View Analyst Ratings for Mirati Therapeutics.
What is the consensus analysts' recommendation for Mirati Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
- 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (5/9/2018)
- 2. Cann analysts commented, "Mirati Therapeutics, Inc. announced today that it has entered into an exclusive license agreement with BeiGene for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati confirmed it will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world." (1/8/2018)
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL), Array Biopharma (ARRY) and OPKO Health (OPK).
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Dr. Rodney W. Lappe, Exec. Chairman (Age 63)
- Dr. Charles M. Baum, Pres, CEO & Director (Age 60)
- Dr. James Christensen, Sr. VP & Chief Scientific Officer (Age 50)
- Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 56)
- Mr. Jamie A. Donadio, Sr. VP & CFO (Age 43)
Has Mirati Therapeutics been receiving favorable news coverage?
Media headlines about MRTX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mirati Therapeutics earned a news impact score of 0.12 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.18 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Mirati Therapeutics?
Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of MRTX stock can currently be purchased for approximately $50.25.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $1.42 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe.
How can I contact Mirati Therapeutics?
Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]
MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
